Abstract

Mutations resulting in reduced or completely abrogated serotonin-transporter (SERT) function in mice have led to the identification of more than 50 different phenotypic changes, ranging from increased anxiety and stress-related behaviours to gut dysfunction, bone weakness and late-onset obesity with metabolic syndrome. These multiple effects, which can be amplified by gene–environment and gene–gene interactions, are primarily attributable to altered intracellular and extracellular serotonin concentrations during development and adulthood. Much of the human data relating to altered expression of the gene that encodes SERT are based on genetic-association findings or correlations and are therefore not as robust as the experimental mouse results. Nevertheless, SERT-function-modifying gene variants in humans apparently produce many phenotypes that are similar to those that manifest themselves in mice.

Author affiliations

1. Laboratory of Clinical Science, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA.
   Email: DennisMurphy@mail.nih.gov
2. Molecular and Clinical Psychobiology, Department of Psychiatry and Psychotherapy, University of Würzburg, 97080 Würzburg, Germany.
   Email: kplesch@mail.uni-wuerzburg.de

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.